Literature DB >> 16986050

Summary of clinical experiences with tamsulosin for the treatment of benign prostatic hyperplasia.

Franklin C Lowe.   

Abstract

Tamsulosin, a uroselective alpha(1A)-adrenergic-receptor antagonist, has been shown to improve lower urinary tract symptoms associated with benign prostatic hyperplasia. It has a better side effect profile than earlier alpha-adrenergic-receptor antagonists, which were initially developed as antihypertensive agents. Clinical trials of 1 year or longer with tamsulosin show high tolerability for the 0.4 mg dose and no significant interaction with other antihypertensive medications.

Entities:  

Year:  2005        PMID： 16986050      PMCID： PMC1477611     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


  11 in total

1.  Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group.

Authors:  H Lepor
Journal:  Urology       Date:  1998-06       Impact factor: 2.649

2.  Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group.

Authors:  H Lepor
Journal:  Urology       Date:  1998-06       Impact factor: 2.649

3.  Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect.

Authors:  F C Lowe
Journal:  Clin Ther       Date:  1997 Jul-Aug       Impact factor: 3.393

4.  A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.

Authors:  B Djavan; M Marberger
Journal:  Eur Urol       Date:  1999       Impact factor: 20.096

5.  A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia).

Authors:  P Abrams; M Speakman; M Stott; D Arkell; R Pocock
Journal:  Br J Urol       Date:  1997-10

6.  Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability?

Authors:  M C Michel; L Mehlburger; H U Bressel; H Schumacher; R F Schäfers; M Goepel
Journal:  J Urol       Date:  1998-09       Impact factor: 7.450

7.  Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.

Authors:  C C Schulman; J Cortvriend; U Jonas; T M Lock; S Vaage; M J Speakman
Journal:  Eur Urol       Date:  1996       Impact factor: 20.096

8.  Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group.

Authors:  P Abrams; C C Schulman; S Vaage
Journal:  Br J Urol       Date:  1995-09

9.  Alpha-1-adrenoceptor blockade in the treatment of benign prostatic hyperplasia.

Authors:  F Lowe
Journal:  Prostate Cancer Prostatic Dis       Date:  1999-05       Impact factor: 5.554

10.  A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group.

Authors:  P Narayan; A Tewari
Journal:  J Urol       Date:  1998-11       Impact factor: 7.450
View more
  3 in total

1.  Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans.

Authors:  Kyoung-Ah Kim; In-Bae Park; Ji-Young Park
Journal:  Eur J Clin Pharmacol       Date:  2018-06-13       Impact factor: 2.953

2.  Ethanol: Unlocking an Abundant Renewable C2 -Feedstock for Catalytic Enantioselective C-C Coupling.

Authors:  Cole C Meyer; Nicholas P Stafford; Melinda J Cheng; Michael J Krische
Journal:  Angew Chem Int Ed Engl       Date:  2021-03-30       Impact factor: 15.336

Review 3.  Terminal Phenoxy Group as a Privileged Moiety of the Drug Scaffold-A Short Review of Most Recent Studies 2013-2022.

Authors:  Paweł Kozyra; Monika Pitucha
Journal:  Int J Mol Sci       Date:  2022-08-09       Impact factor: 6.208
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.